drugset / Trial / NCT04933669
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Phase 2
Recruiting
122 enrolled
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital of Wenzhou Medical University · collabNingbo No. 1 Hospital · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collabSir Run Run Shaw Hospital · collabTaizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved. A few retrospective analyses and a small sample of prospective studies have found that neoadjuvant therapy with imatinib mesylate can improve R0 resection rates. Whether neoadjuvant therapy prolongs long-term survival remains unclear. The primary objective of this study was to evaluate 5-year progression-free survival (PFS) for GIST patients with high recurrence risk after neoadjuvant treatment with imatinib mesylate.
Timeline
- Start
- 2021-09-07
- Primary completion
- 2029-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |